Bright Peak Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 57

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $90M

  • Investors
  • 12

Bright Peak Therapeutics General Information

Description

Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops immuno-cytokines with pharmacological properties that allow tissue and cell-specific targeting through cytokine payload with the added potential for enhanced efficacy, enabling doctors to improve treatment outcomes and quality of life for patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Switzerland Innovation Park Basel Area
  • Hegenheimermattweg 167 D
  • 4123 Allschwil
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Switzerland Innovation Park Basel Area
  • Hegenheimermattweg 167 D
  • 4123 Allschwil
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bright Peak Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 11-Jun-2024 $90M Completed Pre-Clinical Trials
5. Early Stage VC (Series B) 10-Jun-2021 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 28-Jul-2020 Completed Pre-Clinical Trials
3. Early Stage VC 11-Dec-2018 Completed Pre-Clinical Trials
2. Early Stage VC 14-Dec-2017 Completed Startup
1. University Spin-Out 14-Dec-2017 Completed Startup
To view Bright Peak Therapeutics’s complete valuation and funding history, request access »

Bright Peak Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
To view Bright Peak Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bright Peak Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops im
Drug Discovery
Allschwil, Switzerland
57 As of 2025

Pittsburgh, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bright Peak Therapeutics Competitors (1)

One of Bright Peak Therapeutics’s competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytoAgents Venture Capital-Backed Pittsburgh, PA
You’re viewing 1 of 1 competitors. Get the full list »

Bright Peak Therapeutics Patents

Bright Peak Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026139739-A1 Dual binding compositions targeting vegfa and pd-1 Pending 27-Dec-2024
WO-2026083296-A1 Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains Pending 16-Oct-2024
US-20260139053-A1 Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains Pending 16-Oct-2024
US-20260184792-A1 Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains Pending 16-Oct-2024
WO-2026083295-A1 Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains Pending 16-Oct-2024 C07K16/2818
To view Bright Peak Therapeutics’s complete patent history, request access »

Bright Peak Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bright Peak Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson JJDC Corporate Venture Capital Minority
KB Investment Venture Capital Minority
Northleaf Capital Partners PE/Buyout Minority
Venrock Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Bright Peak Therapeutics FAQs

  • When was Bright Peak Therapeutics founded?

    Bright Peak Therapeutics was founded in 2017.

  • Where is Bright Peak Therapeutics headquartered?

    Bright Peak Therapeutics is headquartered in Allschwil, Switzerland.

  • What is the size of Bright Peak Therapeutics?

    Bright Peak Therapeutics has 57 total employees.

  • What industry is Bright Peak Therapeutics in?

    Bright Peak Therapeutics’s primary industry is Drug Discovery.

  • Is Bright Peak Therapeutics a private or public company?

    Bright Peak Therapeutics is a Private company.

  • What is Bright Peak Therapeutics’s current revenue?

    The current revenue for Bright Peak Therapeutics is .

  • How much funding has Bright Peak Therapeutics raised over time?

    Bright Peak Therapeutics has raised $244M.

  • Who are Bright Peak Therapeutics’s investors?

    Johnson & Johnson JJDC, KB Investment, Northleaf Capital Partners, Venrock, and Alexandria Venture Investments are 5 of 12 investors who have invested in Bright Peak Therapeutics.

  • Who are Bright Peak Therapeutics’s competitors?

    CytoAgents is a competitor of Bright Peak Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process